Stake Completed Sponsor buyer
Sixth Street stake in BridgeBio
US$1bn consideration
Announced 1 Jul 2026 · NASDAQ: BBIO
Advisers
BridgeBio
Target
Not disclosed
Sixth Street
Acquirer
- Financial adviser
- Legal adviser
- Target
- BridgeBio
- Acquirer
- Sixth Street
- Target based in
- United States
- Buyer based in
- United States
- Structure
- Minority stake
- Completed
- 1 Jul 2026
- Sector
- Biotech
- Tags
- Biotech, Rare Disease
In the league tables
Similar deals
- Incyte acquisition of Vega Therapeutics Jun 2026 · US$1.3bn · Biotech
- Jazz Pharmaceuticals acquisition of Actio Biosciences Aug 2026 · US$820m · Biotech
- BioCryst Pharmaceuticals acquisition of Astria Therapeutics Oct 2025 · US$700m · Biotech
- Servier acquisition of Sevasemten and Edgewise muscular dystrophy business Jun 2026 · US$1.6bn · Biotech
- Chiesi Group acquisition of KalVista Pharmaceuticals Apr 2026 · US$1.9bn · Pharma
Sources
- 1 Jul 2026 S&C Advises Sixth Street on $1 Billion Preferred Stock Investment in BridgeBio Pharma sullcrom.com
- 1 Jul 2026 Evercore: Advised Sixth Street on its strategic growth investment in BridgeBio evercore.com

